Vestal Point Capital, LP: ARROWHEAD PHARMACEUTICALS INC (ARWR): Quarterly 13F Position History
As of Q1 2026, Vestal Point Capital, LP reported 2,275,000 shares of ARROWHEAD PHARMACEUTICALS INC (ARWR), worth $142.6M and representing 4.0% of its 13F equity book. Quarter-over-quarter share count change: + 1,375,000 (+152.8%) . The position first appeared in Q4 2025 and has been disclosed across 2 13F-HR filings in Pactolio's tracked window.
- 2,275,000Shares Held (Latest Filing)
- $142.6MReported Market Value (Latest Filing)
- 4.0%Portfolio Weight (% of 13F Equity Book)
- +1,375,000Quarter-over-Quarter Share Change
- +$82.9MQuarter-over-Quarter Value Change
- 2,275,000Peak Reported Shares (Historical)
Recent initiation: Vestal Point Capital, LP first reported ARWR on the Q4 2025 filing — fewer than three quarters of history are available.
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 2 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,275,000 | +1,375,000 | +152.8% | $142.6M | 4.0% | $62.7 |
| Q4 2025 | 900,000 | — | — | $59.8M | 2.2% | $66.4 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Vestal Point Capital, LP first disclose a ARWR position in 13F-HR filings?
Vestal Point Capital, LP first reported ARROWHEAD PHARMACEUTICALS INC (ARWR) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 2 reported quarters within Pactolio's tracked window.
What was Vestal Point Capital, LP's most recent quarter-over-quarter share-count change in ARWR?
Between Q4 2025 and Q1 2026, Vestal Point Capital, LP added 1,375,000 shares of ARWR (+152.8%), bringing the total reported position to 2,275,000 shares at a market value of $142.6M.
Does the implied price-per-share represent Vestal Point Capital, LP's cost basis in ARWR?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.